StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cancidas (caspofungin, legacy) — U.S. sales by Quarter

Cancidas (caspofungin, legacy) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Cancidas (caspofungin, legacy) — U.S. sales: $1M in Q4 2022. No newer figure appears in the documents we track.

Latest, Q4 2022
1
Period ended Dec 31, 2022
Change on a year earlier
–
0 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
17
Documents cited below

Where the Q4 2022 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2023-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — U.S. sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 20221–Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 202210.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 20222+100.0%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 20221-66.7%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 20210-100.0%Form 10-K (filed 2023-02-24) ↗
Q3 2021Sep 30, 202110.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 20211-150.0%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2021Mar 31, 202130.0%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2020Dec 31, 20205+150.0%Form 10-K (filed 2023-02-24) ↗
Q3 2020Sep 30, 20201–Form 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2020Jun 30, 2020-2-166.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 20203+200.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201920.0%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 20190-100.0%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 20193-25.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 20191-66.7%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗

Breakdown

What makes up cancidas (caspofungin, legacy) — U.S. sales

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) — U.S. sales ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.